MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/03007995.2025.2517692

Медицинская библиотека · Current medical research and opinion · 2025

Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022).

Colson Amy, Chen Megan, Hennessy Fritha, Gruber Joshua, Zachry Woodie, Park Seojin, Holbrook Tim

СтатьяНаблюдательное исследованиеСравнительное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

This study compared outcomes reported by health care providers (HCPs) and people with HIV (PWH) for individuals prescribed bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus other antiretroviral therapy (ART) regimens.

METHODS

Data were from the Adelphi Real World HIV Disease Specific Programme, an observational, cross-sectional survey of HCPs and PWH conducted from July 2021-March 2022 in the United States. PWH were aged ≥18 years with confirmed HIV and a current ART prescription. Outcomes included HCP- and PWH-reported adherence, treatment satisfaction, quality of life (QoL), and health care resource utilization (HCRU). Subgroups for the primary analysis were based on ART regimen. Comparisons between subgroups were performed using appropriate statistical tests.

RESULTS

Sixty HCPs provided data for 600 PWH, and 249 PWH reported their experiences. Overall, 264 PWH were prescribed B/F/TAF, 281 were prescribed other single-tablet regimens or a long-acting injectable (STRs/LAI), and 55 were prescribed a multi-tablet regimen. Common HCP-reported reasons for choice of ART were viral potency and tolerability. High treatment satisfaction was reported for B/F/TAF by HCPs (61% "very satisfied" with B/F/TAF vs 53% with other STRs/LAI; p = 0.0223) and PWH (57% vs 52%, respectively; p = 0.3170). PWH receiving B/F/TAF reported significantly higher QoL and lower activity impairment versus PWH receiving other STRs/LAI. Adherence rates and HCRU were generally similar between groups.

CONCLUSION

Positive HCP- and PWH-reported outcomes were seen across ART regimens. However, differences observed, including HCP-reported treatment satisfaction and PWH-reported QoL, favored B/F/TAF compared with other STRs/LAI. Findings support continued use of B/F/TAF for HIV treatment in the United States.

Для цитирования: Colson Amy, Chen Megan, Hennessy Fritha, Gruber Joshua, Zachry Woodie, Park Seojin, Holbrook Tim. Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022).. Current medical research and opinion. 2025. DOI: 10.1080/03007995.2025.2517692.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.